Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 Aug;15(8):542-50.
doi: 10.1046/j.1525-1497.2000.03499.x.

Prevalence and duration of postmenopausal hormone replacement therapy use in a managed care organization, 1990-1995

Affiliations

Prevalence and duration of postmenopausal hormone replacement therapy use in a managed care organization, 1990-1995

M T Connelly et al. J Gen Intern Med. 2000 Aug.

Abstract

Objective: To determine the prevalence and duration of postmenopausal hormone replacement therapy (HRT) use and identify correlates of adherence to therapy.

Design: Population-based cohort study.

Setting: Staff-model health maintenance organization.

Participants: Female members, 40 years and older.

Measurements and main results: Prevalence and duration of use were measured between 1990 and 1995. Duration was assessed by Kaplan-Meier and proportional hazards methods. Hormone replacement therapy use increased from 10.3% in 1990 to 20.7% in 1995. Greatest use (24%) occurred among menopausal women age 50 to 54 years. Less than 5% of women 75 and older used HRT. Among 1,680 first-time recipients of HRT, two thirds of initial prescriptions were written by internists. Thirty-eight percent discontinued HRT within 1 year. For the subset whose indication for therapy was ascertained, prevention of chronic disease was associated with a 33% 1-year discontinuation rate. Factors associated with longer duration of therapy included white race (relative risk [RR], 1.63; 95% confidence interval [95% CI], 1.32 to 2.02), younger age (RR, 1.02 per year; 95% CI 1.01 to 1.03), and changing the preparation or dose of estrogen (RR, 5.62; 95% CI, 4.33 to 7.25). The formulation (esterified estrogens 0.625 mg versus conjugated estrogens 0.625 mg) was also associated with greater duration of use; all other estrogens were, as a group, associated with shorter duration of use. Those who received their initial HRT prescription from an internist were more likely to continue therapy than those who received it from a gynecologist.

Conclusions: Despite increased use of HRT, only a minority of women in this population used HRT, and many of those discontinued therapy within 1 year.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Prevalence of hormone replacement therapy use among menopausal women 45 and older, 1990–1995.
FIGURE 2
FIGURE 2
Proportion using hormone replacement therapy by age, 1990–1995.
FIGURE 3
FIGURE 3
Time to discontinuation of hormone replacement therapy (HRT).
FIGURE 3
FIGURE 3
Time to discontinuation of hormone replacement therapy (HRT).

Similar articles

Cited by

References

    1. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016–37. - PubMed
    1. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335:453–61. - PubMed
    1. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med. 1991;325:756–62. - PubMed
    1. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Ann Intern Med. 1995;122:9–16. - PubMed
    1. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med. 1991;151:75–8. - PubMed

Publication types